PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för aclidinium bromide. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

26 hits

Bibliografisk träff 2012-06-01

Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.

de la Motte S, Beier J, Schmid K, Pascual S, Jansat JM, Gil EG.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.5414/cp201628

Bibliografisk träff 2012-02-15

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S.

Pulm Pharmacol Ther · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.pupt.2012.02.002

Bibliografisk träff 2012-02-09

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators.

COPD · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.3109/15412555.2012.661492

Bibliografisk träff 2011-12-22

Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile.

Gavaldà A, Gras J, Llupià J, Aubets J, Beleta J, Llenas J.

Life Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.lfs.2011.12.002

Bibliografisk träff 2011-09-28

Aclidinium inhibits human lung fibroblast to myofibroblast transition.

Milara J, Serrano A, Peiró T, Gavaldà A, Miralpeix M, Morcillo EJ, Cortijo J.

Thorax · research support, non-u.s. gov't; research-article; journal article · DOI 10.1136/thoraxjnl-2011-200376

Bibliografisk träff 2011-09-16

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.

Sims MW, Panettieri RA.

Int J Chron Obstruct Pulmon Dis · review-article; review; journal article · DOI 10.2147/copd.s15524

Bibliografisk träff 2011-09-08

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.

Chest · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1378/chest.11-0406

Bibliografisk träff 2011-05-31

Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.

Ortiz S, Flach S, Caracta C, Gil EG, Jansat JM.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1177/0091270011406281

Bibliografisk träff 2011-03-22

Aclidinium bromide in experimental asthma.

Antoniu SA.

Expert Opin Investig Drugs · comment; journal article · DOI 10.1517/13543784.2011.566865

Bibliografisk träff 2010-12-22

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C.

Respir Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.rmed.2010.11.019

Bibliografisk träff 2010-12-22

In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism.

Albertí JJ, Sentellas S, Salvà M.

Biochem Pharmacol · comparative study; journal article · DOI 10.1016/j.bcp.2010.12.013

Bibliografisk träff 2010-10-19

Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects.

Lasseter KC, Aubets J, Chuecos F, Gil EG.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1177/0091270010374471

Bibliografisk träff 2010-09-30

An update on the efficacy and safety of aclidinium bromide in patients with COPD.

Alagha K, Bourdin A, Tummino C, Chanez P.

Ther Adv Respir Dis · review; journal article · DOI 10.1177/1753465810381546

Bibliografisk träff 2010-09-22

Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation.

Damera G, Jiang M, Zhao H, Fogle HW, Jester WF, Freire J, Panettieri RA.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2010.09.043

Bibliografisk träff 2010-09-01

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM.

Clin Ther · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/j.clinthera.2010.09.002

Bibliografisk träff 2010-05-01

Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study.

Schelfhout VJ, Ferrer P, Jansat JM, Peris F, Gil EG, Pauwels RA, Joos GF.

Br J Clin Pharmacol · research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/j.1365-2125.2010.03622.x

Bibliografisk träff 2010-03-23

Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide.

Albertí J, Martinet A, Sentellas S, Salvà M.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.109.031724

Bibliografisk träff 2010-01-20

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

Sentellas S, Ramos I, Albertí J, Salvà M, Antón F, Miralpeix M, Beleta J, Gavaldà A.

Eur J Pharm Sci · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.ejps.2010.01.004

Bibliografisk träff 2009-12-30

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.

Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.

Respir Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.rmed.2009.12.003

Bibliografisk träff 2009-08-26

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

Gavaldà A, Miralpeix M, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.109.151639

Bibliografisk träff 2009-08-14

Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

Chanez P, Burge PS, Dahl R, Creemers J, Chuchalin A, Lamarca R, Garcia Gil E.

Pulm Pharmacol Ther · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.pupt.2009.08.001

Bibliografisk träff 2009-08-01

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide).

Prat M, Fernández D, Buil MA, Crespo MI, Casals G, Ferrer M, Tort L, Castro J, Monleón JM, Gavaldà A, Miralpeix M, Ramos I, Doménech T, Vilella D, Antón F, Huerta JM, Espinosa S, López M, Sentellas S, González M, Albertí J, Segarra V, Cárdenas A, Beleta J, Ryder H.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm900132z

Bibliografisk träff 2009-07-10

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.

Jansat JM, Lamarca R, de Miquel G, Schrödter A, Miletzki B, Gurniak M.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1177/0091270009336353

Bibliografisk träff 2009-07-01

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.

Jansat JM, Lamarca R, Garcia Gil E, Ferrer P.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.5414/cpp47460

Bibliografisk träff 2009-05-16

Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.

Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G.

Respiration · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1159/000219676

Bibliografisk träff 2009-05-01

Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.

Cazzola M.

Curr Opin Investig Drugs · review; journal article